JP2014517855A - 架橋ポリ−ε−リシン非粒状支持体 - Google Patents
架橋ポリ−ε−リシン非粒状支持体 Download PDFInfo
- Publication number
- JP2014517855A JP2014517855A JP2014505649A JP2014505649A JP2014517855A JP 2014517855 A JP2014517855 A JP 2014517855A JP 2014505649 A JP2014505649 A JP 2014505649A JP 2014505649 A JP2014505649 A JP 2014505649A JP 2014517855 A JP2014517855 A JP 2014517855A
- Authority
- JP
- Japan
- Prior art keywords
- lysine
- polymer
- poly
- support
- cross
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004472 Lysine Substances 0.000 title claims abstract description 107
- 229920000642 polymer Polymers 0.000 claims abstract description 191
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 21
- 239000000835 fiber Substances 0.000 claims abstract description 20
- 239000004971 Cross linker Substances 0.000 claims abstract description 16
- 238000004113 cell culture Methods 0.000 claims abstract description 16
- 238000010532 solid phase synthesis reaction Methods 0.000 claims abstract description 15
- 125000000524 functional group Chemical group 0.000 claims abstract description 13
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims abstract description 8
- -1 carbon amine Chemical class 0.000 claims abstract description 8
- 238000013375 chromatographic separation Methods 0.000 claims abstract description 5
- 230000000717 retained effect Effects 0.000 claims abstract description 5
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 4
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 4
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 102000004190 Enzymes Human genes 0.000 claims description 23
- 108090000790 Enzymes Proteins 0.000 claims description 23
- 239000003431 cross linking reagent Substances 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 21
- 239000007790 solid phase Substances 0.000 claims description 18
- 239000003054 catalyst Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 238000003786 synthesis reaction Methods 0.000 claims description 14
- 206010052428 Wound Diseases 0.000 claims description 13
- 208000027418 Wounds and injury Diseases 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 230000005526 G1 to G0 transition Effects 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 8
- 239000000032 diagnostic agent Substances 0.000 claims description 8
- 229940039227 diagnostic agent Drugs 0.000 claims description 8
- 239000003999 initiator Substances 0.000 claims description 8
- 239000011942 biocatalyst Substances 0.000 claims description 7
- 229920002521 macromolecule Polymers 0.000 claims description 7
- 238000002414 normal-phase solid-phase extraction Methods 0.000 claims description 7
- 230000004069 differentiation Effects 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 238000010647 peptide synthesis reaction Methods 0.000 claims description 6
- 125000001931 aliphatic group Chemical group 0.000 claims description 5
- 239000002609 medium Substances 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 238000013268 sustained release Methods 0.000 claims description 5
- 239000012730 sustained-release form Substances 0.000 claims description 5
- 239000002250 absorbent Substances 0.000 claims description 4
- 230000002745 absorbent Effects 0.000 claims description 4
- 239000003905 agrochemical Substances 0.000 claims description 4
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 4
- 238000002515 oligonucleotide synthesis Methods 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 239000002904 solvent Substances 0.000 abstract description 5
- 239000008204 material by function Substances 0.000 abstract description 3
- 230000029663 wound healing Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 41
- 235000018102 proteins Nutrition 0.000 description 22
- 210000001671 embryonic stem cell Anatomy 0.000 description 21
- 239000011148 porous material Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 238000004132 cross linking Methods 0.000 description 19
- 241000894007 species Species 0.000 description 19
- 239000000047 product Substances 0.000 description 16
- 239000007787 solid Substances 0.000 description 15
- 238000004587 chromatography analysis Methods 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 150000001412 amines Chemical group 0.000 description 10
- 125000003277 amino group Chemical group 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 8
- 108010010803 Gelatin Proteins 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- 229920006037 cross link polymer Polymers 0.000 description 8
- TVIDDXQYHWJXFK-UHFFFAOYSA-N dodecanedioic acid Chemical compound OC(=O)CCCCCCCCCCC(O)=O TVIDDXQYHWJXFK-UHFFFAOYSA-N 0.000 description 8
- 239000008273 gelatin Substances 0.000 description 8
- 229920000159 gelatin Polymers 0.000 description 8
- 235000019322 gelatine Nutrition 0.000 description 8
- 235000011852 gelatine desserts Nutrition 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 210000004102 animal cell Anatomy 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000007791 liquid phase Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 229920002239 polyacrylonitrile Polymers 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 210000002304 esc Anatomy 0.000 description 5
- 239000000446 fuel Substances 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 210000004116 schwann cell Anatomy 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000004367 Lipase Substances 0.000 description 4
- 102000004882 Lipase Human genes 0.000 description 4
- 108090001060 Lipase Proteins 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000007987 MES buffer Substances 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 238000006555 catalytic reaction Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 235000019421 lipase Nutrition 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 239000003361 porogen Substances 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108010039918 Polylysine Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 210000002199 attachment cell Anatomy 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000003225 biodiesel Substances 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 229960003067 cystine Drugs 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 230000003100 immobilizing effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 229920000656 polylysine Polymers 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108010093096 Immobilized Enzymes Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000004115 adherent culture Methods 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000003688 hormone derivative Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000005065 mining Methods 0.000 description 2
- 239000002121 nanofiber Substances 0.000 description 2
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 2
- 229910000510 noble metal Inorganic materials 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical group [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000005518 polymer electrolyte Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- QFGCFKJIPBRJGM-UHFFFAOYSA-N 12-[(2-methylpropan-2-yl)oxy]-12-oxododecanoic acid Chemical compound CC(C)(C)OC(=O)CCCCCCCCCCC(O)=O QFGCFKJIPBRJGM-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- 241001536303 Botryococcus braunii Species 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010073038 Penicillin Amidase Proteins 0.000 description 1
- 101710123388 Penicillin G acylase Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000002210 biocatalytic effect Effects 0.000 description 1
- 239000002551 biofuel Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000011243 crosslinked material Substances 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 238000012674 dispersion polymerization Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 238000010556 emulsion polymerization method Methods 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 108010046301 glucose peroxidase Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000011810 insulating material Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012229 microporous material Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 238000007040 multi-step synthesis reaction Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052757 nitrogen Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000002685 polymerization catalyst Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/48—Polymers modified by chemical after-treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/12—Powdering or granulating
- C08J3/126—Polymer particles coated by polymer, e.g. core shell structures
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D177/00—Coating compositions based on polyamides obtained by reactions forming a carboxylic amide link in the main chain; Coating compositions based on derivatives of such polymers
- C09D177/04—Polyamides derived from alpha-amino carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/06—Enzymes or microbial cells immobilised on or in an organic carrier attached to the carrier via a bridging agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
- C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- C12N11/096—Polyesters; Polyamides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
- C12N11/098—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer formed in the presence of the enzymes or microbial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/432—Inhibitors, antagonists
- A61L2300/434—Inhibitors, antagonists of enzymes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2477/00—Characterised by the use of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Derivatives of such polymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/249921—Web or sheet containing structurally defined element or component
- Y10T428/249953—Composite having voids in a component [e.g., porous, cellular, etc.]
- Y10T428/249987—With nonvoid component of specified composition
- Y10T428/249991—Synthetic resin or natural rubbers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2991—Coated
- Y10T428/2998—Coated including synthetic resin or polymer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
ポリ−ε−リシン(200mg、アミン含有量1mmol)を、DMF/水(2.45cm3、1:1v/v)に溶解し、NMM(0.137cm3、1.2mmol)、続いてグルタル酸無水物(70mg、グルタル酸無水物0.6mmol、すなわちアミンに対して過剰量)を添加した。反応を2時間進行させた。
水(100cm3)中にポリ−ε−リシン(4.93g、アミン含有量28.7mmol)、ドデカン二酸(3.47g、カルボキシル含有量30mmol)および水酸化ナトリウム(1.15g、28.7mmol)を含有する溶液を調製した。
上のシートから切断されたスーパーマクロポーラスディスクをリン酸緩衝食塩水(3×PBS)で洗浄し、30分間紫外線を照射し、その後細胞を接触させた。
上のシートから切断されたスーパーマクロポーラスディスクをリン酸緩衝食塩水(3×PBS)で洗浄し、30分間紫外線を照射し、その後細胞を接触させた。
スーパーマクロポーラスポリマーの試料を12ウェルの組織培養皿のウェルに三重に置き、1時間紫外線殺菌し、その後試料をシュワン細胞成長培地[SCGM(DMEM+10%FBS+GGF+フォルスコリン)]に水和させた。2つの細胞密度(シュワン細胞500,000および50,000)を、SCGM中のそれぞれのスーパーマクロポーラスポリマーの足場の上に播種した。アラマーブルー吸光度アッセイを使用して、細胞増殖を試験した。
水(100cm3)中にポリ−ε−リシン(4.93g、アミン含有量28.7mmol)、ドデカン二酸(3.47g、カルボキシル含有量30mmol)および水酸化ナトリウム(1.15g、28.7mmol)を含有する溶液を調製した。
水(10cm3)中にポリ−ε−リシン(0.49g、アミン含有量2.9mmol)、ドデカン二酸(0.35g、カルボキシル含有量3.0mmol)および水酸化ナトリウム(0.115g、2.9mmol)を含有する溶液を調製した。
rプロテインAの架橋ポリ−ε−リシンへのカップリング
N−ヒドロキシスクシンイミド(1g)を冷MES緩衝液(25mmol/dm3、pH5.0、2.5cm3)に溶解し、EDCI(1g)を溶解したMES緩衝液(25mmol/dm3、pH5.0、2.5cm3)と混合した。この溶液を、HPLCポンプを使用してモノリスに通した。モノリスをMES緩衝液(25mmol/dm3、pH5.0、50cm3)で洗浄し、直ちにrプロテインA(25mmol/dm3MES、pH5.0中に5cm3、4mg/cm3)の溶液をカラム上にかけ、一晩静置した。モノリスをTrizma−HCl(30cm3 pH7.4)で洗浄し、ポリマー上の残りのN−ヒドロキシスクシンイミドエステルをすべてブロックした。モノリスを水(100cm3)で洗浄し、水中で保存した。
DMSO(6cm3)中にポリアクリロニトリル(0.8g、平均分子量150,000)、ポリ−ε−リシン(0.4g)およびセバシン酸(0.24g)を含有する溶液を、電界紡糸し(24kV、0.5cm3/時)、40℃および湿度30%の回転ドラム上に移した。
水(1.5cm3)中にポリ−ε−リシン(0.49g、アミン含有量2.9mmol)、セバシン酸(0.15g、カルボキシル含有量1.45mmol)および水酸化ナトリウム(0.06g、1.5mmol)を含有する溶液を調製した。
レンズの写真を図12に示す。
Claims (23)
- 非粒状の架橋ポリ−ε−リシンポリマー。
- アミド結合によって連結された、ポリ−ε−リシンと架橋剤とを含む、請求項1に記載のポリマー。
- ポリ−ε−リシンのアルファ炭素のアミンと反応することができる少なくとも2つの官能基を含む架橋剤で架橋される、請求項1または2に記載のポリマー。
- 架橋剤が、2つ以上のカルボン酸基と、該2つ以上の基を連結する脂肪族鎖とを含む、請求項1〜3のいずれか一項に記載のポリマー。
- 水に不溶性である、請求項1〜4のいずれか一項に記載のポリマー。
- 多孔質である、請求項1〜5のいずれか一項に記載のポリマー。
- 請求項1〜6のいずれか一項に記載のポリマーを含む、非粒状支持体。
- 架橋ポリ−ε−リシン支持体が、非粒状媒体を直接的にまたは間接的にコーティングするために使用される、請求項7に記載の非粒状支持体。
- 架橋ポリ−ε−リシン支持体が、非粒状媒体をコーティングするために使用され、かつ非粒状媒体に共有結合される、請求項7または8に記載の非粒状支持体。
- 架橋ポリ−ε−リシンが、有機非粒状媒体をコーティングするために使用される、請求項7〜9のいずれか一項に記載の非粒状支持体。
- 架橋ポリ−ε−リシンが、無機非粒状媒体をコーティングするために使用される、請求項7から9のいずれか一項に記載の非粒状支持体。
- 架橋ポリ−ε−リシンが官能化されて、触媒、ペプチド合成の開始剤種、オリゴヌクレオチド合成の開始剤種、固相有機合成の開始剤種、薬学的活性物質、農薬的活性物質、クロマトグラフ分離用の表面、細胞培養または分化を促進するための種、タンパク質または他の生体巨大分子を含む材料をもたらす、請求項7〜11のいずれかに記載の非粒状架橋ポリ−ε−リシンベースの支持体。
- 請求項1〜6のいずれか一項に記載の架橋ポリ−ε−リシンを含む、三次元構造体。
- ミクロポーラス、マクロポーラスまたは繊維である、請求項13に記載の三次元構造体。
- 架橋ポリ−ε−リシンでコーティングされた請求項13または14に記載の三次元マクロポーラス構造体であって、コーティングするために使用される架橋ポリ−ε−リシンが、ミクロポーラス、マクロポーラスまたは繊維構造体に直接的または間接的に共有結合される、三次元マクロポーラス構造体。
- 架橋ポリ−ε−リシンでコーティングされた請求項13または14に記載の三次元マクロポーラス構造体であって、コーティングするために使用される架橋ポリ−ε−リシンが、ミクロポーラス、マクロポーラスまたは繊維構造体に共有結合されない、三次元マクロポーラス構造体。
- 架橋ポリ−ε−リシンが官能化されて、触媒、ペプチド合成の開始剤種、オリゴヌクレオチド合成の開始剤種、固相有機合成の開始剤種、薬学的活性物質、農薬的活性物質、クロマトグラフ分離用の表面、細胞培養または分化を促進するための種、タンパク質または他の生体巨大分子を含む材料をもたらす、請求項13〜16のいずれか一項に記載の三次元架橋ポリ−ε−リシンベースの支持体。
- 請求項1〜6のいずれか一項に記載のポリマーまたは請求項7〜17のいずれか一項に記載の支持体を含む、シート、物品、または繊維。
- 請求項1〜6のいずれか一項に記載のポリマーもしくは請求項7〜17のいずれか一項に記載の支持体、および創傷を治療するための成分もしくは組成物、ならびに/または治療剤を含む、創傷治療製品。
- ポリマーまたは支持体がシートの形状である、請求項19に記載の創傷治療製品。
- 請求項7〜178のいずれか一項に記載の非粒状支持体を含み、かつ該支持体に結合したまたは保持される機能材料を含む、医学的診断薬。
- 機能材料が、ポリマーによって担持される酵素を含む、請求項21に記載の医学的診断薬。
- ペプチド、オリゴヌクレオチド、オリゴ糖の固相合成;固相抽出;固相有機化学;固相試薬、金属触媒および他の触媒、生体触媒、酵素、タンパク質、ポリクローナル抗体およびモノクローナル抗体を含めた抗体、細胞全体ならびにポリマーから選択される種の固定化;細胞培養;クロマトグラフ分離用固定相の調製から選択されるプロセスにおける、あるいは吸収剤としてまたは徐放製品用の生分解性担体として使用するための、請求項7〜17のいずれか一項に記載の非粒状支持体の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201106742A GB201106742D0 (en) | 2011-04-20 | 2011-04-20 | Cross-linked poly-e-lysine |
GB1106742.8 | 2011-04-20 | ||
PCT/EP2012/057271 WO2013041250A1 (en) | 2011-04-20 | 2012-04-20 | Cross-linked poly-e-lysine non-particulate support |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014517855A true JP2014517855A (ja) | 2014-07-24 |
JP6240062B2 JP6240062B2 (ja) | 2017-11-29 |
Family
ID=44147334
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014505649A Active JP6240062B2 (ja) | 2011-04-20 | 2012-04-20 | 架橋ポリ−ε−リシン非粒状支持体 |
JP2014505646A Active JP6262645B2 (ja) | 2011-04-20 | 2012-04-20 | 架橋ポリ−ε−リシン粒子 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014505646A Active JP6262645B2 (ja) | 2011-04-20 | 2012-04-20 | 架橋ポリ−ε−リシン粒子 |
Country Status (14)
Country | Link |
---|---|
US (3) | US20140154737A1 (ja) |
EP (2) | EP2699619B1 (ja) |
JP (2) | JP6240062B2 (ja) |
KR (2) | KR101976151B1 (ja) |
CN (2) | CN103619911B (ja) |
AU (1) | AU2012244686B2 (ja) |
CA (2) | CA2833589C (ja) |
DK (2) | DK2699619T3 (ja) |
ES (2) | ES2673515T3 (ja) |
GB (3) | GB201106742D0 (ja) |
HU (2) | HUE036430T2 (ja) |
PT (2) | PT2699620T (ja) |
WO (2) | WO2013041250A1 (ja) |
ZA (2) | ZA201307921B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022107876A1 (ja) * | 2020-11-20 | 2022-05-27 | 株式会社堀場製作所 | 捕捉用デバイス |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201106742D0 (en) * | 2011-04-20 | 2011-06-01 | Spheritech Ltd | Cross-linked poly-e-lysine |
EP2826785B1 (en) * | 2012-03-13 | 2017-08-09 | National University Corporation Okayama University | Lysine oligomer derivative and cartilage tissue marker made thereof |
GB201503566D0 (en) * | 2015-03-03 | 2015-04-15 | Spheritech Ltd | Microparticles |
WO2017011618A1 (en) * | 2015-07-15 | 2017-01-19 | The Curators Of The University Of Missouri | Targeted nanoparticle conjugate and method for co-delivery of sirna and drug |
GB201615047D0 (en) * | 2016-09-05 | 2016-10-19 | Spheritech Ltd | Microparticle composition and use thereof |
GB201615050D0 (en) * | 2016-09-05 | 2016-10-19 | Spheritech Ltd | Microparticles |
CN106784869B (zh) * | 2017-02-14 | 2019-09-27 | 安徽正熹标王新能源有限公司 | 一种燃料电池 |
EP3592787A4 (en) * | 2017-03-10 | 2021-01-20 | University of Florida Research Foundation | MICROGEL PARTICLES FOR USE IN 3D PRINTING AND 3D CELL GROWTH MEDIA, AND RELATED COMPOSITIONS, SYSTEMS, AND METHODS |
JP6624746B2 (ja) * | 2018-03-06 | 2019-12-25 | 国立大学法人北陸先端科学技術大学院大学 | 凍結による細胞内分子導入法 |
WO2021067952A1 (en) * | 2019-10-04 | 2021-04-08 | The University Of Chicago | Targeted nanomedicine for treating vascular disorders |
CN110804175B (zh) * | 2019-11-08 | 2021-05-14 | 中国科学院理化技术研究所 | 一种交替结构抗菌聚氨基酸衍生物或共聚物及其制备方法 |
CN114350590B (zh) * | 2021-12-24 | 2024-06-25 | 大连大学 | 一种离子响应微胶囊及其制备方法与应用 |
GB202404078D0 (en) | 2024-03-21 | 2024-05-08 | Spheritech Ltd | Aqueus-phase synthesis method |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05501543A (ja) * | 1989-12-11 | 1993-03-25 | イムノメデイツクス・インコーポレイテツド | 診断薬または治療薬の抗体ターゲティング |
JPH08502498A (ja) * | 1992-10-30 | 1996-03-19 | ノボ ノルディスク アクティーゼルスカブ | 低アレルゲン性タンパク質 |
JPH10501706A (ja) * | 1994-04-04 | 1998-02-17 | コラーゲン コーポレイション | 細胞−ゲル |
JP2000070356A (ja) * | 1994-05-13 | 2000-03-07 | Kuraray Co Ltd | 医療用高分子ゲル |
JP2005053974A (ja) * | 2003-08-06 | 2005-03-03 | Chisso Corp | 多糖架橋体及びその製造法。 |
JP2006307004A (ja) * | 2005-04-28 | 2006-11-09 | Osaka Univ | ポリアミノ酸を構成成分とするハイドロゲル |
WO2007061058A1 (ja) * | 2005-11-24 | 2007-05-31 | Osaka University | 刺激応答性分解ゲル |
US20080292675A1 (en) * | 2007-03-09 | 2008-11-27 | Erich Edermatt | Antimicrobial medicotechnical product, process for its production and use |
US20080292671A1 (en) * | 2005-09-09 | 2008-11-27 | Aesculap Ag & Co. Kg | Antimicrobial Medicotechnical Product, Process for its Preparation and Use |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61205864A (ja) | 1985-03-09 | 1986-09-12 | Meidensha Electric Mfg Co Ltd | 免疫学的固相測定試薬とその調製法 |
JPH01126557A (ja) | 1987-11-11 | 1989-05-18 | Meidensha Corp | 免疫測定用試薬 |
WO1990013256A1 (en) * | 1989-05-04 | 1990-11-15 | Wisconsin Alumni Research Foundation | Method for localization and treatment of tumors and complexes therefor |
EP0665729B1 (en) * | 1992-09-04 | 2003-05-07 | The General Hospital Corporation | Biocompatible polymers containing diagnostic or therapeutic moieties |
JP4606524B2 (ja) | 1997-11-19 | 2011-01-05 | チッソ株式会社 | ポリリジン、及びポリリジンの製造方法、及びポリリジン組成物、及びエンドトキシンを除去する医薬品の生産方法 |
US6660301B1 (en) | 1998-03-06 | 2003-12-09 | Biosphere Medical, Inc. | Injectable microspheres for dermal augmentation and tissue bulking |
JP2001126557A (ja) | 1999-10-27 | 2001-05-11 | Sumitomo Wiring Syst Ltd | ワイヤハーネスの製造方法およびワイヤハーネス |
JP2001128659A (ja) | 1999-11-09 | 2001-05-15 | Chisso Corp | 細胞培養用粒状マイクロキャリア |
JP2003033651A (ja) * | 2001-07-24 | 2003-02-04 | Chisso Corp | 経口リン吸着剤及びそれを含む食品 |
JP2003171464A (ja) * | 2001-12-06 | 2003-06-20 | Chisso Corp | ポリリジン及びその製造方法 |
JP2003176353A (ja) * | 2001-12-13 | 2003-06-24 | Chisso Corp | ポリリジン及びその製造方法 |
US7834065B2 (en) | 2005-01-31 | 2010-11-16 | Bmg Incorporated | Medical-use two part reactive adhesive and medical-use resin having self-degradation property |
CN1850301A (zh) * | 2006-03-03 | 2006-10-25 | 清华大学 | 一种中枢神经修复用水凝胶材料及其制备方法 |
GB0614727D0 (en) | 2006-07-25 | 2006-09-06 | Chromatide Ltd | Solid support |
WO2008149473A1 (ja) * | 2007-06-07 | 2008-12-11 | National University Corporation Kanazawa University | 心筋パッド |
WO2009057802A1 (ja) * | 2007-11-01 | 2009-05-07 | Osaka City University | β-1,3-グルカン由来ポリアルデヒド/ポリアミンハイドロゲル |
EP2277547A1 (de) | 2009-07-20 | 2011-01-26 | Merck Patent GmbH | Epsilon-Polylysin-Konjugate und deren Verwendung |
GB2473814B (en) | 2009-09-16 | 2014-06-11 | Spheritech Ltd | Hollow particulate support |
GB201106742D0 (en) * | 2011-04-20 | 2011-06-01 | Spheritech Ltd | Cross-linked poly-e-lysine |
-
2011
- 2011-04-20 GB GB201106742A patent/GB201106742D0/en not_active Ceased
-
2012
- 2012-04-20 WO PCT/EP2012/057271 patent/WO2013041250A1/en active Application Filing
- 2012-04-20 PT PT127242956T patent/PT2699620T/pt unknown
- 2012-04-20 EP EP12721432.8A patent/EP2699619B1/en active Active
- 2012-04-20 ES ES12724295.6T patent/ES2673515T3/es active Active
- 2012-04-20 CN CN201280028657.8A patent/CN103619911B/zh not_active Expired - Fee Related
- 2012-04-20 DK DK12721432.8T patent/DK2699619T3/en active
- 2012-04-20 KR KR1020137030699A patent/KR101976151B1/ko active IP Right Grant
- 2012-04-20 KR KR1020137030695A patent/KR101953865B1/ko active IP Right Grant
- 2012-04-20 GB GB1320463.1A patent/GB2504641B/en active Active
- 2012-04-20 ES ES12721432.8T patent/ES2662902T3/es active Active
- 2012-04-20 HU HUE12721432A patent/HUE036430T2/hu unknown
- 2012-04-20 EP EP12724295.6A patent/EP2699620B1/en active Active
- 2012-04-20 JP JP2014505649A patent/JP6240062B2/ja active Active
- 2012-04-20 WO PCT/EP2012/057264 patent/WO2012143508A1/en active Application Filing
- 2012-04-20 DK DK12724295.6T patent/DK2699620T3/en active
- 2012-04-20 US US14/112,731 patent/US20140154737A1/en active Pending
- 2012-04-20 US US14/112,742 patent/US9938378B2/en active Active
- 2012-04-20 PT PT127214328T patent/PT2699619T/pt unknown
- 2012-04-20 GB GB201320466A patent/GB2504439B/en active Active
- 2012-04-20 CA CA2833589A patent/CA2833589C/en active Active
- 2012-04-20 AU AU2012244686A patent/AU2012244686B2/en active Active
- 2012-04-20 HU HUE12724295A patent/HUE038184T2/hu unknown
- 2012-04-20 CA CA2833695A patent/CA2833695C/en active Active
- 2012-04-20 JP JP2014505646A patent/JP6262645B2/ja active Active
- 2012-04-20 CN CN201280028453.4A patent/CN103597011B/zh not_active Expired - Fee Related
-
2013
- 2013-10-23 ZA ZA2013/07921A patent/ZA201307921B/en unknown
- 2013-10-23 ZA ZA2013/07922A patent/ZA201307922B/en unknown
-
2018
- 2018-03-15 US US15/922,281 patent/US10266652B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05501543A (ja) * | 1989-12-11 | 1993-03-25 | イムノメデイツクス・インコーポレイテツド | 診断薬または治療薬の抗体ターゲティング |
JPH08502498A (ja) * | 1992-10-30 | 1996-03-19 | ノボ ノルディスク アクティーゼルスカブ | 低アレルゲン性タンパク質 |
JPH10501706A (ja) * | 1994-04-04 | 1998-02-17 | コラーゲン コーポレイション | 細胞−ゲル |
JP2000070356A (ja) * | 1994-05-13 | 2000-03-07 | Kuraray Co Ltd | 医療用高分子ゲル |
JP2005053974A (ja) * | 2003-08-06 | 2005-03-03 | Chisso Corp | 多糖架橋体及びその製造法。 |
JP2006307004A (ja) * | 2005-04-28 | 2006-11-09 | Osaka Univ | ポリアミノ酸を構成成分とするハイドロゲル |
US20080292671A1 (en) * | 2005-09-09 | 2008-11-27 | Aesculap Ag & Co. Kg | Antimicrobial Medicotechnical Product, Process for its Preparation and Use |
WO2007061058A1 (ja) * | 2005-11-24 | 2007-05-31 | Osaka University | 刺激応答性分解ゲル |
US20080292675A1 (en) * | 2007-03-09 | 2008-11-27 | Erich Edermatt | Antimicrobial medicotechnical product, process for its production and use |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022107876A1 (ja) * | 2020-11-20 | 2022-05-27 | 株式会社堀場製作所 | 捕捉用デバイス |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10266652B2 (en) | Cross-linked poly-E-lysine non-particulate support | |
JP5789261B2 (ja) | 中空微粒子体 | |
JP6810050B2 (ja) | 微粒子 | |
JP2007319074A (ja) | ナノファイバーを含む新規スキャフォールドおよびその用途 | |
EP3714034A1 (en) | A bioactive 3d encapsulation culture system for cell expansion | |
AU2012311912B2 (en) | Cross-linked poly-e-lysine non-particulate support | |
Zhou et al. | Microspheres for cell culture | |
US7645721B2 (en) | End group activated polymers with oligonucleotide ligands | |
JPH0833474A (ja) | 付着性動物細胞の培養基体 | |
GB2562004B (en) | Cross-linked poly-e-lysine particles | |
JPH0833473A (ja) | 付着性動物細胞の培養基体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150413 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160408 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160414 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160714 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160914 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161014 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170329 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170731 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170807 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171025 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171102 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6240062 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |